APA (7th ed.) Citation

Fujii, H., Hirano, H., Shoji, H., Okita, N., & Kato, K. (2026). Bridging the Evidence Gap in Small Bowel Adenocarcinoma: Current Standards, Biomarker-selected Therapies and Novel Antibody–Drug Conjugate-based Clinical Initiatives. touchREVIEWS in Oncology & Haematology, 22(1), 9. https://doi.org/10.17925/OHR.2026.22.1.4

Chicago Style (17th ed.) Citation

Fujii, Hiroyuki, Hidekazu Hirano, Hirokazu Shoji, Natsuko Okita, and Ken Kato. "Bridging the Evidence Gap in Small Bowel Adenocarcinoma: Current Standards, Biomarker-selected Therapies and Novel Antibody–Drug Conjugate-based Clinical Initiatives." TouchREVIEWS in Oncology & Haematology 22, no. 1 (2026): 9. https://doi.org/10.17925/OHR.2026.22.1.4.

MLA (9th ed.) Citation

Fujii, Hiroyuki, et al. "Bridging the Evidence Gap in Small Bowel Adenocarcinoma: Current Standards, Biomarker-selected Therapies and Novel Antibody–Drug Conjugate-based Clinical Initiatives." TouchREVIEWS in Oncology & Haematology, vol. 22, no. 1, 2026, p. 9, https://doi.org/10.17925/OHR.2026.22.1.4.